For Chinese translation click here
点击此处查看中文翻译
TauRx Therapeutics Management Ltd can confirm it has received formal confirmation from the UK Medicines and Healthcare products Regulatory Agency (MHRA) that it requires some further information before a final determination on the suitability of hydromethylthionine mesylate (HMTM), as a potential oral treatment for Alzheimer’s disease, can be reached.
TauRx colleagues are in the process of working through the request in order to ensure answers are collated as expediently as is practicable.
The company is committed to working with the MHRA and other organisations as required, and further updates will be provided in due course.
TauRx 确认已收到英国药品和保健品管理局 (MHRA) 的正式通知. 该局表示在确定口服 HMTM 作为阿尔茨海默病治疗方案的适用性前，尚需补充更多信息。
TauRx团队正全力响应该要求，确保尽快完成信息整理工作。
TauRx 承诺将与MHRA及其他相关机构保持密切协作，后续进展将适时公布。
